Skip to main content
Erschienen in: Inflammation 1/2012

01.02.2012

Antihypertensive Drugs and Inflammation in Acute Ischemic Stroke as a Predictor Factor of Future Cardiovascular Mortality

verfasst von: Gulcin Benbir, Birsen Ince, Emre Kumral, Zeki Ongen, Hakan Kultursay, Lale Tokgozoglu, Ali Oto, Hasan Tuzun, on the behalf of ARDA Investigators

Erschienen in: Inflammation | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

The beneficial effects of antihypertensive drugs in secondary stroke prevention could not be based on their effects on lowering hypertension only.In this prospective study, the status of blood pressure, treatment regimens, new atherothrombotic event, blood sampling for hs-CRP and fibrinogen were asked at initial visit, 6th, and 12th months in 226 patients with atherothrombotic stroke.Eighty-seven percent of patients had an antihypertensive regimen, but hypertension control was achieved in 34.1% of patients.Neither use of six different antihypertensive drug regimens nor the change in blood pressure levels showed any difference on new atherothrombotic events, outcomes or survival rates.On the other hand, the higher levels of hs-CRP at baseline were found to be associated with higher mortality rates(p = 0.020).Our findings emphasize the predictive role of inflammation in future cardiovascular mortality in patients with acute ischemic stroke, indicating that inflammatory mediators underlying the atherothrombotic process play a more important role than it is assumed.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Preston, R.A. 2007. Effects of blood pressure reduction on cardiovascular risk estimates in hypertensive postmenopausal women. Climacteric 10: 32–41.PubMedCrossRef Preston, R.A. 2007. Effects of blood pressure reduction on cardiovascular risk estimates in hypertensive postmenopausal women. Climacteric 10: 32–41.PubMedCrossRef
2.
Zurück zum Zitat Volpe, M., G. Tocci, B. Trimarco, E.A. Rosei, C. Borghi, E. Ambrosioni, A. Menotti, A. Zanchetti, and G. Mancia. 2007. Blood pressure control in Italy: Results of recent surveys on hypertension. Journal of Hypertension 25: 1491–1498.PubMedCrossRef Volpe, M., G. Tocci, B. Trimarco, E.A. Rosei, C. Borghi, E. Ambrosioni, A. Menotti, A. Zanchetti, and G. Mancia. 2007. Blood pressure control in Italy: Results of recent surveys on hypertension. Journal of Hypertension 25: 1491–1498.PubMedCrossRef
3.
Zurück zum Zitat Chobanian, A.V., G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, J.L. Izzo Jr., D.W. Jones, B.J. Materson, S. Oparil, J.T. Wright Jr., E.J. Roccella, Joint National Committee on Prevention, Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National Heart, Lung, and Blood Institute, and National High Blood Pressure Education Program Coordinating Committee. 2003. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 42: 1206–1252.PubMedCrossRef Chobanian, A.V., G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, J.L. Izzo Jr., D.W. Jones, B.J. Materson, S. Oparil, J.T. Wright Jr., E.J. Roccella, Joint National Committee on Prevention, Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National Heart, Lung, and Blood Institute, and National High Blood Pressure Education Program Coordinating Committee. 2003. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 42: 1206–1252.PubMedCrossRef
4.
Zurück zum Zitat Chobanian, A.V., G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, J.L. Izzo Jr., D.W. Jones, B.J. Materson, S. Oparil, J.T. Wright Jr., E.J. Roccella, National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, and National High Blood Pressure Education Program Coordinating Committee. 2003. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289: 2560–2572.PubMedCrossRef Chobanian, A.V., G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, J.L. Izzo Jr., D.W. Jones, B.J. Materson, S. Oparil, J.T. Wright Jr., E.J. Roccella, National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, and National High Blood Pressure Education Program Coordinating Committee. 2003. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289: 2560–2572.PubMedCrossRef
5.
Zurück zum Zitat Neal, B., S. MacMahon, and N. Chapman. 2000. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs. Lancet 356: 1955–1964.PubMedCrossRef Neal, B., S. MacMahon, and N. Chapman. 2000. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs. Lancet 356: 1955–1964.PubMedCrossRef
6.
Zurück zum Zitat PROGRESS Collaborative Group. 2001. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 358: 1033–1041.CrossRef PROGRESS Collaborative Group. 2001. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 358: 1033–1041.CrossRef
7.
Zurück zum Zitat Staessen, J.A., R. Fagard, L. Thijs, H. Celis, G.G. Arabidze, W.H. Birkenhäger, C.J. Bulpitt, P.W. de Leeuw, C.T. Dollery, A.E. Fletcher, F. Forette, G. Leonetti, C. Nachev, E.T. O’Brien, J. Rosenfeld, J.L. Rodicio, J. Tuomilehto, and A. Zanchetti. 1997. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 350: 757–764.PubMedCrossRef Staessen, J.A., R. Fagard, L. Thijs, H. Celis, G.G. Arabidze, W.H. Birkenhäger, C.J. Bulpitt, P.W. de Leeuw, C.T. Dollery, A.E. Fletcher, F. Forette, G. Leonetti, C. Nachev, E.T. O’Brien, J. Rosenfeld, J.L. Rodicio, J. Tuomilehto, and A. Zanchetti. 1997. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 350: 757–764.PubMedCrossRef
8.
Zurück zum Zitat Hansson, L., T. Hedner, and F.B. Dahlo. 1992. Prospective, randomized, open blinded end-point (PROBE) study. A novel design for interventional trials. Blood Pressure 1: 113–119.PubMedCrossRef Hansson, L., T. Hedner, and F.B. Dahlo. 1992. Prospective, randomized, open blinded end-point (PROBE) study. A novel design for interventional trials. Blood Pressure 1: 113–119.PubMedCrossRef
9.
Zurück zum Zitat Ovbiagele, B., N.K. Hills, J.L. Saver, S.C. Johnston, and for the CASPR Investigators. 2005. Cerebrovascular event antihypertensive medications prescribed at discharge after an acute ischemic. Stroke 36: 1944–1947.PubMedCrossRef Ovbiagele, B., N.K. Hills, J.L. Saver, S.C. Johnston, and for the CASPR Investigators. 2005. Cerebrovascular event antihypertensive medications prescribed at discharge after an acute ischemic. Stroke 36: 1944–1947.PubMedCrossRef
10.
Zurück zum Zitat Bonita, R., and R. Beaglehole. 1988. Modification of Rankin scale: Recovery of motor function after stroke. Stroke 19: 1497–1500.PubMedCrossRef Bonita, R., and R. Beaglehole. 1988. Modification of Rankin scale: Recovery of motor function after stroke. Stroke 19: 1497–1500.PubMedCrossRef
11.
Zurück zum Zitat Wade, D.T., and C. Collin. 1988. The Barthel ADL Index: A standard measure of physical disability? International Disability Studies 10: 64–67.PubMedCrossRef Wade, D.T., and C. Collin. 1988. The Barthel ADL Index: A standard measure of physical disability? International Disability Studies 10: 64–67.PubMedCrossRef
12.
Zurück zum Zitat Mahoney, F.I., and D.W. Barthel. 1965. Functional evaluation: The Barthel index. Maryland State Medical Journal 14: 61–65.PubMed Mahoney, F.I., and D.W. Barthel. 1965. Functional evaluation: The Barthel index. Maryland State Medical Journal 14: 61–65.PubMed
13.
Zurück zum Zitat MOSES Study Group. 2005. Controlled study (MOSES) for secondary prevention: Principal results of a prospective randomized morbidity and mortality after stroke, eprosartan compared with nitrendipine. Stroke 36: 1218–1224.CrossRef MOSES Study Group. 2005. Controlled study (MOSES) for secondary prevention: Principal results of a prospective randomized morbidity and mortality after stroke, eprosartan compared with nitrendipine. Stroke 36: 1218–1224.CrossRef
14.
Zurück zum Zitat Di Napoli, M., M. Schwaninger, R. Cappelli, E. Ceccarelli, G. Di Gianfilippo, C. Donati, H.C.A. Emsley, S. Forconi, S.J. Hopkins, L. Masotti, K.W. Muir, A. Paciucci, F. Papa, S. Roncacci, D. Sander, K. Sander, C.J. Smith, A. Stefanini, and D. Weber. 2005. Evaluation of C-Reactive protein measurement for assessing the risk and prognosis in ischemic stroke. A statement for health care professionals from the CRP pooling. Stroke 36: 1316–29.PubMedCrossRef Di Napoli, M., M. Schwaninger, R. Cappelli, E. Ceccarelli, G. Di Gianfilippo, C. Donati, H.C.A. Emsley, S. Forconi, S.J. Hopkins, L. Masotti, K.W. Muir, A. Paciucci, F. Papa, S. Roncacci, D. Sander, K. Sander, C.J. Smith, A. Stefanini, and D. Weber. 2005. Evaluation of C-Reactive protein measurement for assessing the risk and prognosis in ischemic stroke. A statement for health care professionals from the CRP pooling. Stroke 36: 1316–29.PubMedCrossRef
15.
Zurück zum Zitat Sung, K.C., J.Y. Sh, B.S. Kim, J.H. Kang, H. Kim, M.H. Lee, J.R. Park, and S.W. Kim. 2003. High sensitivity C-reactive protein as an independent risk factor for essential hypertension. American Journal of Hypertension 16: 429–433.PubMedCrossRef Sung, K.C., J.Y. Sh, B.S. Kim, J.H. Kang, H. Kim, M.H. Lee, J.R. Park, and S.W. Kim. 2003. High sensitivity C-reactive protein as an independent risk factor for essential hypertension. American Journal of Hypertension 16: 429–433.PubMedCrossRef
16.
Zurück zum Zitat Bautista, L.E., P. Lopez-Jaramillo, L.M. Vera, J.P. Casas, A.P. Otero, and A.I. Guaracao. 2001. Is C-reactive protein an independent risk factor for essential hypertension? Journal of Hypertension 19: 857–861.PubMedCrossRef Bautista, L.E., P. Lopez-Jaramillo, L.M. Vera, J.P. Casas, A.P. Otero, and A.I. Guaracao. 2001. Is C-reactive protein an independent risk factor for essential hypertension? Journal of Hypertension 19: 857–861.PubMedCrossRef
17.
Zurück zum Zitat Benbir, G., M. Bozluolcay, and B. Ince. 2005. Is the level of C-reactive protein correlated with the extent of carotid atherosclerosis? Acta Neurologica Belgica 105: 73–80.PubMed Benbir, G., M. Bozluolcay, and B. Ince. 2005. Is the level of C-reactive protein correlated with the extent of carotid atherosclerosis? Acta Neurologica Belgica 105: 73–80.PubMed
18.
Zurück zum Zitat Dahlof, B., R.B. Devereux, S.E. Kjeldsen, S. Julius, G. Beevers, U. de Faire, F. Fyhrquist, H. Ibsen, K. Kristiansson, O. Lederballe-Pedersen, L.H. Lindholm, M.S. Nieminen, P. Omvik, S. Oparil, H. Wedel, and LIFE Study Group. 2002. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 359: 995–1003.PubMedCrossRef Dahlof, B., R.B. Devereux, S.E. Kjeldsen, S. Julius, G. Beevers, U. de Faire, F. Fyhrquist, H. Ibsen, K. Kristiansson, O. Lederballe-Pedersen, L.H. Lindholm, M.S. Nieminen, P. Omvik, S. Oparil, H. Wedel, and LIFE Study Group. 2002. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 359: 995–1003.PubMedCrossRef
19.
Zurück zum Zitat Schrader, J., M. Rothemeyer, S. Luders, and K. Kollmann. 1998. Hypertension and stroke–rationale behind the ACCESS trial. Acute candesartan cilexetil evaluation in stroke survivors. Basic Research in Cardiology 93: 69–78.PubMedCrossRef Schrader, J., M. Rothemeyer, S. Luders, and K. Kollmann. 1998. Hypertension and stroke–rationale behind the ACCESS trial. Acute candesartan cilexetil evaluation in stroke survivors. Basic Research in Cardiology 93: 69–78.PubMedCrossRef
20.
Zurück zum Zitat Schrader, J., S. Lüders, A. Kulschewski, J. Berger, W. Zidek, J. Treib, K. Einhäupl, H.C. Diener, P. Dominiak, and Acute candesartan cilexetil therapy in stroke survivors study group. 2003. The ACCESS study: Evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 34: 1699–1703.PubMedCrossRef Schrader, J., S. Lüders, A. Kulschewski, J. Berger, W. Zidek, J. Treib, K. Einhäupl, H.C. Diener, P. Dominiak, and Acute candesartan cilexetil therapy in stroke survivors study group. 2003. The ACCESS study: Evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 34: 1699–1703.PubMedCrossRef
21.
Zurück zum Zitat PATS Collaborating Group. 1995. Post-stroke antihypertensive treatment study. A preliminary result. Chinese Medical Journal 108: 710–717. PATS Collaborating Group. 1995. Post-stroke antihypertensive treatment study. A preliminary result. Chinese Medical Journal 108: 710–717.
22.
Zurück zum Zitat Thone-Reineke, C., U.M. Steckelings, and T. Unger. 2006. Angiotensin receptor blockers and cerebral protection in stroke. Journal of Hypertension. Supplement 24: 115–121.CrossRef Thone-Reineke, C., U.M. Steckelings, and T. Unger. 2006. Angiotensin receptor blockers and cerebral protection in stroke. Journal of Hypertension. Supplement 24: 115–121.CrossRef
23.
Zurück zum Zitat Heart Outcome Prevention Evaluation Study Investigators. 2000. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The New England Journal of Medicine 342: 145–153.CrossRef Heart Outcome Prevention Evaluation Study Investigators. 2000. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The New England Journal of Medicine 342: 145–153.CrossRef
24.
Zurück zum Zitat Qureshi, A., M.F. Suri, L.R. Guterman, and L.N. Hopkins. 2001. Ineffective secondary prevention in survivors of cardiovascular events in the US population: Report from the third national health and nutrition examination survey. Archives of Internal Medicine 161: 1621–1628.PubMedCrossRef Qureshi, A., M.F. Suri, L.R. Guterman, and L.N. Hopkins. 2001. Ineffective secondary prevention in survivors of cardiovascular events in the US population: Report from the third national health and nutrition examination survey. Archives of Internal Medicine 161: 1621–1628.PubMedCrossRef
25.
Zurück zum Zitat Hillen, T., R. Dundas, E. Lawrence, J.A. Stewart, A.G. Rudd, and C.D. Wolfe. 2000. Antithrombotic and antihypertensive management 3 months after ischemic stroke: A prospective study in an inner city population. Stroke 31: 469–475.PubMedCrossRef Hillen, T., R. Dundas, E. Lawrence, J.A. Stewart, A.G. Rudd, and C.D. Wolfe. 2000. Antithrombotic and antihypertensive management 3 months after ischemic stroke: A prospective study in an inner city population. Stroke 31: 469–475.PubMedCrossRef
26.
Zurück zum Zitat Law, M., N.J. Wald, J.K. Morris, and R.E. Jordan. 2003. Value of low-dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomised trials. BMJ 326: 1427.PubMedCrossRef Law, M., N.J. Wald, J.K. Morris, and R.E. Jordan. 2003. Value of low-dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomised trials. BMJ 326: 1427.PubMedCrossRef
27.
Zurück zum Zitat Khan, N., F.A. McAlister, N.R. Campbell, R.D. Feldman, S. Rabkin, J. Mahon, R. Lewanczuk, K.B. Zarnke, B. Hemmelgarn, M. Lebel, M. Levine, C. Herbert, and Canadian Hypertension Education Program. 2004. The 2004 Canadian recommendations for the management of hypertension: Part II-therapy. The Canadian Journal of Cardiology 20: 41–54.PubMed Khan, N., F.A. McAlister, N.R. Campbell, R.D. Feldman, S. Rabkin, J. Mahon, R. Lewanczuk, K.B. Zarnke, B. Hemmelgarn, M. Lebel, M. Levine, C. Herbert, and Canadian Hypertension Education Program. 2004. The 2004 Canadian recommendations for the management of hypertension: Part II-therapy. The Canadian Journal of Cardiology 20: 41–54.PubMed
28.
Zurück zum Zitat Cao, J.J., C. Thach, T.A. Manolio, B.M. Psaty, L.H. Kuller, P.H. Chaves, J.F. Polak, K. Sutton-Tyrrell, D.M. Herrington, T.R. Price, and M. Cushman. 2003. C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: The cardiovascular health study. Circulation 108: 166–170.PubMedCrossRef Cao, J.J., C. Thach, T.A. Manolio, B.M. Psaty, L.H. Kuller, P.H. Chaves, J.F. Polak, K. Sutton-Tyrrell, D.M. Herrington, T.R. Price, and M. Cushman. 2003. C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: The cardiovascular health study. Circulation 108: 166–170.PubMedCrossRef
29.
Zurück zum Zitat Hashimoto, H., K. Kitagawa, H. Hougaku, H. Etani, and M. Hori. 2004. Relationship between C-reactive protein and progression of early carotid atherosclerosis in hypertensive subjects. Stroke 35: 1625–1630.PubMedCrossRef Hashimoto, H., K. Kitagawa, H. Hougaku, H. Etani, and M. Hori. 2004. Relationship between C-reactive protein and progression of early carotid atherosclerosis in hypertensive subjects. Stroke 35: 1625–1630.PubMedCrossRef
30.
Zurück zum Zitat Muir, K.W., C.J. Weir, W. Alwan, I.B. Squire, and K.R. Lees. 1999. C-reactive protein and outcome after ischemic stroke. Stroke 30: 981–985.PubMedCrossRef Muir, K.W., C.J. Weir, W. Alwan, I.B. Squire, and K.R. Lees. 1999. C-reactive protein and outcome after ischemic stroke. Stroke 30: 981–985.PubMedCrossRef
31.
Zurück zum Zitat Di Napoli, M., and F. Papa. 2003. Association between blood pressure and c-reactive protein levels in acute ischemic stroke. Hypertension 42: 1117–1123.PubMedCrossRef Di Napoli, M., and F. Papa. 2003. Association between blood pressure and c-reactive protein levels in acute ischemic stroke. Hypertension 42: 1117–1123.PubMedCrossRef
32.
Zurück zum Zitat Fulop, T., A.D. Rule, D.W. Schmidt, H.J. Wiste, K.R. Bailey, I.J. Kullo, G.L. Schwartz, T.H. Mosley, E. Boerwinkle, and S.T. Turner. 2009. C-reactive protein among community-dwelling hypertensives on single-agent antihypertensive treatment. J Am Soc Hypertens 3: 260–266.PubMedCrossRef Fulop, T., A.D. Rule, D.W. Schmidt, H.J. Wiste, K.R. Bailey, I.J. Kullo, G.L. Schwartz, T.H. Mosley, E. Boerwinkle, and S.T. Turner. 2009. C-reactive protein among community-dwelling hypertensives on single-agent antihypertensive treatment. J Am Soc Hypertens 3: 260–266.PubMedCrossRef
33.
Zurück zum Zitat Palmas, W., S. Ma, B. Psaty, D.C. Goff, C. Darwin, and R.G. Barr. 2007. Antihypertensive medications and C-reactive protein in the muli-ethnic study of atherosclerosis. American Journal of Hypertension 20: 233–241.PubMedCrossRef Palmas, W., S. Ma, B. Psaty, D.C. Goff, C. Darwin, and R.G. Barr. 2007. Antihypertensive medications and C-reactive protein in the muli-ethnic study of atherosclerosis. American Journal of Hypertension 20: 233–241.PubMedCrossRef
Metadaten
Titel
Antihypertensive Drugs and Inflammation in Acute Ischemic Stroke as a Predictor Factor of Future Cardiovascular Mortality
verfasst von
Gulcin Benbir
Birsen Ince
Emre Kumral
Zeki Ongen
Hakan Kultursay
Lale Tokgozoglu
Ali Oto
Hasan Tuzun
on the behalf of ARDA Investigators
Publikationsdatum
01.02.2012
Verlag
Springer US
Erschienen in
Inflammation / Ausgabe 1/2012
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-010-9290-4

Weitere Artikel der Ausgabe 1/2012

Inflammation 1/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.